FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2548888906> ?p ?o ?g. }

• W2548888906 endingPage "CMC.S38448" @default.
• W2548888906 startingPage "CMC.S38448" @default.
• W2548888906 abstract "Introduction Critical limb ischemia (CLI) is defined by ischemic rest pain, tissue loss, or both, secondary to arterial insufficiency, and its prevalence is increasing mainly as a result of the worldwide high prevalence of diabetes. Currently, there are no available conclusive data on the efficacy of any coadjuvant therapy after revascularization procedure benefiting amputation and patency rates. Macitentan is an orally active dual endothelin (ET) receptor antagonist that may contribute to reduce the amputation rate and improve revascularization patency in CLI. Methods/Design REVASC is a proposed pilot, open-label, controlled, randomized, single-center clinical double-blind trial to be conducted in Spain on a study population of European patients with CLI, which will compare the clinical outcomes and cost-effectiveness of macitentan coadjuvant treatment after limb revascularization with the standard antiplatelet treatment strategy for severe limb ischemia. Patients are randomized 1:1 to receive macitentan or placebo for 12 weeks. The primary clinical end point will be amputation-free survival rate at 12 months, defined as the time to major (above the ankle) amputation for the index (trial) limb or death from any cause, whichever comes first. Secondary outcomes include overall survival, quality of life, in-hospital mortality and morbidity, repeat interventions, healing of tissue loss, and hemodynamic changes following revascularization. Sample size is estimated as 120 patients. The economic analysis will consist of two components: a “within-study” analysis, which will be based on study end points; and a “model-based” analysis, which will extrapolate and compare costs and effects likely to accrue beyond the study follow-up period. Discussion The REVASC trial is designed to be pragmatic and represents current practice of the real-world population management after limb revascularization for CLI due to atherosclerosis. Current evidence does not support any coadjuvant treatment. A new pathway of treatment may be opened with the use of ET receptor antagonists in these patients." @default.
• W2548888906 created "2016-11-11" @default.
• W2548888906 creator A5002866521 @default.
• W2548888906 creator A5012658828 @default.
• W2548888906 creator A5065418490 @default.
• W2548888906 creator A5065637009 @default.
• W2548888906 creator A5077567111 @default.
• W2548888906 creator A5080119662 @default.
• W2548888906 date "2016-01-01" @default.
• W2548888906 modified "2023-10-16" @default.
• W2548888906 title "Rationale and Design of Randomized Clinical Trial for the Assessment of Macitentan Efficiency as Coadjuvant Treatment to Open and Endovascular Revascularization in Critical Limb Ischemia" @default.
• W2548888906 cites W1936863318 @default.
• W2548888906 cites W1984441748 @default.
• W2548888906 cites W1984684769 @default.
• W2548888906 cites W1985326793 @default.
• W2548888906 cites W2000923296 @default.
• W2548888906 cites W2020243806 @default.
• W2548888906 cites W2025896576 @default.
• W2548888906 cites W2089946259 @default.
• W2548888906 cites W2111260323 @default.
• W2548888906 cites W2116384002 @default.
• W2548888906 cites W2121978193 @default.
• W2548888906 cites W2132326230 @default.
• W2548888906 cites W2144985796 @default.
• W2548888906 cites W2158862125 @default.
• W2548888906 cites W2163951953 @default.
• W2548888906 cites W2204892343 @default.
• W2548888906 cites W2294671516 @default.
• W2548888906 cites W2494057768 @default.
• W2548888906 cites W4231595983 @default.
• W2548888906 cites W4236878386 @default.
• W2548888906 cites W4290764582 @default.
• W2548888906 cites W4297067663 @default.
• W2548888906 doi "https://doi.org/10.4137/cmc.s38448" @default.
• W2548888906 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5096766" @default.
• W2548888906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27840580" @default.
• W2548888906 hasPublicationYear "2016" @default.
• W2548888906 type Work @default.
• W2548888906 sameAs 2548888906 @default.
• W2548888906 citedByCount "1" @default.
• W2548888906 countsByYear W25488889062022 @default.
• W2548888906 crossrefType "journal-article" @default.
• W2548888906 hasAuthorship W2548888906A5002866521 @default.
• W2548888906 hasAuthorship W2548888906A5012658828 @default.
• W2548888906 hasAuthorship W2548888906A5065418490 @default.
• W2548888906 hasAuthorship W2548888906A5065637009 @default.
• W2548888906 hasAuthorship W2548888906A5077567111 @default.
• W2548888906 hasAuthorship W2548888906A5080119662 @default.
• W2548888906 hasBestOaLocation W25488889061 @default.
• W2548888906 hasConcept C126322002 @default.
• W2548888906 hasConcept C141071460 @default.
• W2548888906 hasConcept C142724271 @default.
• W2548888906 hasConcept C168563851 @default.
• W2548888906 hasConcept C203092338 @default.
• W2548888906 hasConcept C204787440 @default.
• W2548888906 hasConcept C27081682 @default.
• W2548888906 hasConcept C2776204877 @default.
• W2548888906 hasConcept C2779464278 @default.
• W2548888906 hasConcept C2781099653 @default.
• W2548888906 hasConcept C2908647359 @default.
• W2548888906 hasConcept C500558357 @default.
• W2548888906 hasConcept C535046627 @default.
• W2548888906 hasConcept C71924100 @default.
• W2548888906 hasConcept C99454951 @default.
• W2548888906 hasConceptScore W2548888906C126322002 @default.
• W2548888906 hasConceptScore W2548888906C141071460 @default.
• W2548888906 hasConceptScore W2548888906C142724271 @default.
• W2548888906 hasConceptScore W2548888906C168563851 @default.
• W2548888906 hasConceptScore W2548888906C203092338 @default.
• W2548888906 hasConceptScore W2548888906C204787440 @default.
• W2548888906 hasConceptScore W2548888906C27081682 @default.
• W2548888906 hasConceptScore W2548888906C2776204877 @default.
• W2548888906 hasConceptScore W2548888906C2779464278 @default.
• W2548888906 hasConceptScore W2548888906C2781099653 @default.
• W2548888906 hasConceptScore W2548888906C2908647359 @default.
• W2548888906 hasConceptScore W2548888906C500558357 @default.
• W2548888906 hasConceptScore W2548888906C535046627 @default.
• W2548888906 hasConceptScore W2548888906C71924100 @default.
• W2548888906 hasConceptScore W2548888906C99454951 @default.
• W2548888906 hasLocation W25488889061 @default.
• W2548888906 hasLocation W25488889062 @default.
• W2548888906 hasLocation W25488889063 @default.
• W2548888906 hasLocation W25488889064 @default.
• W2548888906 hasOpenAccess W2548888906 @default.
• W2548888906 hasPrimaryLocation W25488889061 @default.
• W2548888906 hasRelatedWork W1995098598 @default.
• W2548888906 hasRelatedWork W2051254937 @default.
• W2548888906 hasRelatedWork W2057000108 @default.
• W2548888906 hasRelatedWork W2597189572 @default.
• W2548888906 hasRelatedWork W2605470762 @default.
• W2548888906 hasRelatedWork W2622265452 @default.
• W2548888906 hasRelatedWork W3120789202 @default.
• W2548888906 hasRelatedWork W3203463092 @default.
• W2548888906 hasRelatedWork W4200056906 @default.
• W2548888906 hasRelatedWork W3023559804 @default.
• W2548888906 hasVolume "10" @default.
• W2548888906 isParatext "false" @default.
• W2548888906 isRetracted "false" @default.

• next